Clinical Trial Update: The Effect of 3% Diquafosol Ophthalmic Solution on Visual Display Terminal-associated Dry Eye [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the effect of 3% diquafosol ophthalmic solution on visual display terminal-associated dry eye and related symptoms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthenopia
• Computer Vision Syndrome
• Dry Eye Syndromes

Drugs mentioned

• 3% diquafosol ophthalmic solution (diquafosol)

Snippet

Sponsor: Peking University Third Hospital | Conditions: Dry Eye Syndromes, Computer Vision Syndrome | Phase 4 | Status: UNKNOWN